Long acting paliperidone injection in patient with bipolar affective disorder, current episode manic with psychotic symptoms: A case report

Wati Wati; I Ketut Arya Santosa; I Gusti Rai Putra Wiguna

doi:10.21744/ijhms.v7n2.2275

Authors

Wati
watilin97@gmail.com
Bali Mental Health Clinic, Denpasar, Indonesia
I Ketut Arya Santosa Bali Mental Health Clinic, Denpasar, Indonesia
I Gusti Rai Putra Wiguna Bali Mental Health Clinic, Denpasar, Indonesia

Keywords:

bipolar disorder, long-acting injectable, manic episode, paliperidone, second-generation antipsychotics

Abstract

Bipolar Disorder is a chronic mental illness characterized by periods of mania, depression, and mixed episodes that often need lifelong medication. The first line of pharmacotherapy includes lithium, valproate, or second-generation antipsychotics. Paliperidone is a medication that works in the brain and is also known as a second-generation antipsychotic. Paliperidone is available as an oral extended-release tablet and a once-monthly extended-release suspension for intramuscular injection. Long-acting injectables (LAIs) are used to reduce the non-adherence of oral medication. Paliperidone is one of the LAI that could be used to treat manic, hypomanic, and mixed episodes in patients with bipolar disorder. Paliperidone LAI reduces the number of relapses, hospitalization, and length of stay. As reported in this case, a patient with a manic episode who received paliperidone LAI showed favourable results after a week-long observation with no signs of extrapyramidal symptoms.

Downloads

Download data is not yet available.

References

American Association of Psychiatric Pharmacists (AAPP). National Alliance on Mental Illness. Paliperidone (Invega). [Online] August 08, 2023. https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication/Paliperidone-(Invega)

American Society of Health-System Pharmacists. Paliperidone. Drug Information 2013. [Online] August 08, 2023.https://pubchem.ncbi.nlm.nih.gov/compound/Paliperidone#section=Structures

Buoli, M., Ciappolino, V., & Altamura, A. C. (2015). Paliperidone palmitate depot in the long-term treatment of psychotic bipolar disorder: a case series. Clinical Neuropharmacology, 38(5), 209-211.

Caliskan, A. M., Calisir, S., Caliskan, S., Arslan, M., Inanli, I., & Eren, I. (2020). Impact of initiating long-acting injectable paliperidone palmitate on relapse and hospitalization in patients with bipolar I disorder: a mirror image retrospective study. Asian Journal of Psychiatry, 54, 102457. https://doi.org/10.1016/j.ajp.2020.102457

Chakrabarti, S. (2022). Bipolar disorder in the International Classification of Diseases-Eleventh version: A review of the changes, their basis, and usefulness. World journal of psychiatry, 12(12), 1335.

Cipriani, A., Barbui, C., Salanti, G., Rendell, J., Brown, R., Stockton, S., ... & Geddes, J. R. (2011). Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet, 378(9799), 1306-1315.

Duffy, A., Alda, M., Hajek, T., Sherry, S. B., & Grof, P. (2010). Early stages in the development of bipolar disorder. Journal of affective disorders, 121(1-2), 127-135. https://doi.org/10.1016/j.jad.2009.05.022

Fraguas, D., Correll, C. U., Merchán-Naranjo, J., Rapado-Castro, M., Parellada, M., Moreno, C., & Arango, C. (2011). Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. European Neuropsychopharmacology, 21(8), 621-645. https://doi.org/10.1016/j.euroneuro.2010.07.002

Gentile, S. (2018). Safety concerns associated with second-generation antipsychotic long-acting injection treatment. A systematic update. Hormone Molecular Biology and Clinical Investigation, 36(2), 20170004.

Gigante, A. D., Lafer, B., & Yatham, L. N. (2012). Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder. CNS drugs, 26, 403-420.

Keramatian, K., Chakrabarty, T., & Yatham, L. N. (2019). Long-acting injectable second-generation/atypical antipsychotics for the management of bipolar disorder: a systematic review. CNS drugs, 33, 431-456.

Li, H., Rui, Q., Ning, X., Xu, H., & Gu, N. (2011). A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35(4), 1002-1008. https://doi.org/10.1016/j.pnpbp.2011.02.001

Misawa, F., Kishimoto, T., Hagi, K., Kane, J. M., & Correll, C. U. (2016). Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophrenia research, 176(2-3), 220-230. https://doi.org/10.1016/j.schres.2016.07.018

Morris, M. T., & Tarpada, S. P. (2017). Long-acting injectable paliperidone palmitate: a review of efficacy and safety. Psychopharmacology Bulletin, 47(2), 42.

National Center for Biotechnology Information. Paliperidone. PubChem Compound Summary for CID 115237. [Online] August 09, 2023.https://pubchem.ncbi.nlm.nih.gov/compound/Paliperidone#section=Drug-Indication

Quraishi, S., & Frangou, S. (2002). Neuropsychology of bipolar disorder: a review. Journal of affective disorders, 72(3), 209-226. https://doi.org/10.1016/S0165-0327(02)00091-5

Riebesehl, B. U. (2015). Drug delivery with organic solvents or colloidal dispersed systems. In The Practice of Medicinal Chemistry (pp. 699-722). Academic Press. https://doi.org/10.1016/B978-0-12-417205-0.00029-8

Rowland, T. A., & Marwaha, S. (2018). Epidemiology and risk factors for bipolar disorder. Therapeutic advances in psychopharmacology, 8(9), 251-269.

Schreiner, A., Aadamsoo, K., Altamura, A. C., Franco, M., Gorwood, P., Neznanov, N. G., ... & Hargarter, L. (2015). Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophrenia research, 169(1-3), 393-399. https://doi.org/10.1016/j.schres.2015.08.015

Stahl, S. M., & Stahl, S. M. (2000). Essential psychopharmacology: Neuroscientific basis and practical applications. Cambridge University Press.

Sugiharta, A. D. N. ., Windiani, I. G. A. T., Adnyana, I. G. A. N. S., & Ardani, I. G. A. I. (2022). Erocive gastritis with bipolar affective disorder current episode severe depression with psychotic symptoms with history of sexual violence in adolescent. International Journal of Health & Medical Sciences, 5(4), 323-326. https://doi.org/10.21744/ijhms.v5n4.1995

Taylor, D. M., Barnes, T. R., & Young, A. H. (2021). The Maudsley prescribing guidelines in psychiatry. John Wiley & Sons.

Vieta, E., Montgomery, S., Sulaiman, A. H., Cordoba, R., Huberlant, B., Martinez, L., & Schreiner, A. (2012). A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. European Neuropsychopharmacology, 22(11), 825-835. https://doi.org/10.1016/j.euroneuro.2012.03.004

Zuddas, A., Zanni, R., & Usala, T. (2011). Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. European Neuropsychopharmacology, 21(8), 600-620. https://doi.org/10.1016/j.euroneuro.2011.04.001